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Abstract
Imaging is critical in the diagnosis and treatment of dementia, particularly in vascular cognitive impairment, due to
the visualization of ischemic and hemorrhagic injury of gray and white matter. Magnetic resonance imaging (MRI)
and positron emission tomography (PET) provide structural and functional information. Clinical MRI is both generally
available and versatile – T2-weighted images show infarcts, FLAIR shows white matter changes and lacunar infarcts,
and susceptibility-weighted images reveal microbleeds. Diffusion MRI adds another dimension by showing graded
damage to white matter, making it more sensitive to white matter injury than FLAIR. Regions of neuroinflammatory
disruption of the blood–brain barrier with increased permeability can be quantified and visualized with dynamic
contrast-enhanced MRI. PET shows metabolism of glucose and accumulation of amyloid and tau, which is useful
in showing abnormal metabolism in Alzheimer’s disease. Combining MRI and PET allows identification of patients
with mixed dementia, with MRI showing white matter injury and PET demonstrating regional impairment of
glucose metabolism and deposition of amyloid. Excellent anatomical detail can be observed with 7.0-Tesla MRI.
Imaging is the optimal method to follow the effect of treatments since changes in MRI scans are seen prior to
those in cognition. This review describes the role of various imaging modalities in the diagnosis and treatment of
vascular cognitive impairment.
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Background
Vascular etiologies are among the most common causes
of dementia, but the numbers vary considerably accord-
ing to the different criteria used for vascular cognitive
impairment (VCI) [1, 2]. According to a controlled
neuropathological study, pure vascular disease is respon-
sible for 8–10 %, Alzheimer’s disease (AD) for 60–70 %,
and dementia with Lewy bodies (DLB) for 10–25 % of
dementia cases [3]. In the Rochester Epidemiology Project
of 419 old demented patients, the post mortem diagnosis
of AD was established in 51 %, of pure vascular dementia
in 13 %, and of mixed vascular-Alzheimer dementia in
12 % of patients, with “other” diagnosis in the remaining
patients [4].
Furthermore, it is evident from autopsy studies that
many patients with mixed dementia have both vascular
and degenerative causes [3, 5]. The heterogeneity of
patients included in the VCI diagnosis has resulted in
attempts to refine the definitions and identify subgroups
of patients [6]. The three main causes of VCI are large ves-
sel strokes (macroangiopathy, arteriosclerosis), small vessel
disease (SVD; microangiopathy, arteriolosclerosis), and
microhemorrhages. Large vessel disease may cause throm-
bosis or embolus with or without involvement of white
matter [7]. SVD causes incomplete or complete infarcts,
lacunar infarcts in both white matter and subcortical gray
matter nuclei, and diffuse injury in white matter [8]. A
characteristic feature of SVD is the sparing of U-fibers that
connect adjacent regions of the cortex. The growth of
white matter hyperintensities (WMHs) occurs gradually
over many years. Large population studies have reported
that FLAIR imaging shows changes in white matter [9];
however, many elderly people over the age of 65 show
white matter changes on magnetic resonance imaging
(MRI) that do not necessarily correspond with symptoms
[10]. These changes in white matter are referred to as
leukoaraiosis, which is a non-specific term to indicate
rarefied white matter for which the underlying pathology
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is not known, and it should not be used to imply a
symptom-producing lesion [11]. Since clinical signs and
symptoms are often insufficient to allow for a final diagno-
sis and usually cannot differentiate among the various
etiologies, neuroimaging plays an important role in the
management of patients with impaired cognition.
Methods
For this review, based on the lectures presented at the
International Congress of Vascular Dementia in Ljubljana
2015, additional literature was searched in PubMed
and relevant publications were selected with special
prioritization to publications published over the last
10 years. Due to limitations in space, a complete coverage
of the extensive literature on this widespread topic was
not possible.
Correlating neuroimaging with morphologic substrates
Neuroimaging provides important information on the
neuroanatomical substrate of the disorder, plays an im-
portant role in the diagnosis, and adds to the prediction
of VCI. Most acute stroke patients undergo brain im-
aging by computed tomography (CT); thus, studies using
CT are representative of the whole clinical population.
In clinical practice, CT is performed primarily to exclude
hemorrhage and stroke mimics (such as brain tumors),
and can often demonstrate early signs of ischemia (e.g.,
swelling, hypodensity, and hyperdense vessels) and old
stroke lesions. Furthermore, the presence and severity of
WMHs and brain atrophy can also be readily determined
from CT brain scans, which may predict subsequent cog-
nitive impairment and dementia. There is good agreement
between brain atrophy and moderate to severe white
matter lesions on CT and MRI measurements [12, 13].
MRI remains the key neuroimaging modality in VCI
(review in [14]). Unless contraindicated, MRI is preferred
to CT for research and routine clinical use due to its
higher sensitivity and specificity for detecting pathological
changes [15]. Standards for neuroimaging with a widely
accepted terminology permitting comparison of findings
between centers have been recommended (STandards for
ReportIng Vascular changes on nEuroimaging, STRIVE)
[16]. Numerous studies identified MRI markers of SVD
(lacunes, WMHs, cerebral microbleeds, silent infarcts,
cerebral atrophy) as determinants of VCI. Vascular lesions
traditionally attributed to VCI comprise subcortical areas
of the brain, especially subfrontal white matter circuits,
strategic areas of single infarction such as the dominant
thalamus or angular gyrus, deep frontal areas and the left
hemisphere, and bilateral brain infarcts or volume-driven
cortical-subcortical infarctions reaching a critical thresh-
old of tissue loss or injury [17]. Multiple punctuate or con-
fluent lesions can be seen in white matter by MRI and are
termed leukoaraiosis [11], which is a non-specific term;
these changes are often seen in healthy elderly subjects
and in subjects with migraine. SVD often causes incom-
plete infarcts. Extended subcortical SVD may be associ-
ated with the pathology of Binswanger’s disease [18].
Some studies have suggested a threshold of 10 cm2 [19] or
25 % of total white matter [20] as the lesion load to affect
cognition. Incomplete infarcts present as hyperintensities
on FLAIR images, whereas complete infarcts present as
hypointense lesions in relation to the brain and isointense
to the cerebrospinal fluid.
The third major neuroimaging aspect of VCI are
microhemorrhages, and were found in up to 65 % of
VCI cases [21]. Macrohemorrhages associated with
cognitive impairment (e.g., venous infarcts) can be seen on
conventional T1- and T2-weighted spin echo images,
microhemorrhages can be detected accurately using T2*-
weighted gradient echo images [22]. Microhemorrhages
and white matter changes not only occur in vascular de-
mentia but also in neurodegenerative diseases [23, 24]. In
addition, recent papers have suggested that only minor
percentages of WMHs on MRI are explained by hyperten-
sion [25], and even microbleeds can be caused by other
novel factors such as infection [26].
High resolution MRI for neuropathological investigation
of vascular dementia syndromes
7.0-Tesla (T) MRI can be used as an additional tool to
examine post mortem brains of patients with neurodegen-
erative and vascular dementia syndromes [27]. High-field
MRI shows the degree and the distribution of the cerebral
atrophy, and it detects lesions that can be selected for
histological examination. Small cerebrovascular lesions
can be quantified and the iron load evaluated.
High-resolution 7.0-T MRI allows detection of cortical
microinfarcts in vivo [28]. There is some evidence that
cortical microinfarcts can be visualized in vivo at a 3.0-T
field strength using newer sequences such as double in-
version recovery [29]. However, this finding has not been
verified histopathologically. A recent study has found
some supportive evidence for use of double-inversion re-
covery sequence as a marker of cortical ischemic lesions
based on the relationship with carotid atherosclerosis
[30]. Further studies with a focus on clinicopathological
correlation are required before these sequences will find
their way into clinical practice.
Detection of small cortical bleeds has a reliability of
96 % [31] since cortical microbleeds predominate to a
different degree in the frontal areas of all neurodegenera-
tive disease groups compared to the controls [32]. Cortical
microinfarcts are more frequent in vascular dementia, in
Lewy body, and in AD associated with severe cerebral
amyloid angiopathy [33]. Cerebellar microinfarcts, on the
other hand, are mainly due to atherosclerotic disease [34].
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Lacunes and white matter changes are mainly observed
in vascular dementia brains. The latter are also frequently
seen in frontotemporal lobar degeneration due to
Wallerian degeneration, rather than caused by cerebro-
vascular disease [35]. Superficial siderosis is due to hemo-
siderin deposition in the subpial layer and is associated
with an underlying cortical lesion, which can be either
a hemorrhage or an infarct after hemorrhagic trans-
formation [36]. Iron deposition in the basal ganglia is
significantly increased in frontotemporal lobar degen-
eration [37].
Diffusion MRI in SVD and cognitive decline
Cognitive decline in healthy ageing and age-related disor-
ders is related to cortical “disconnection” – white matter
damage leading to reduced functional integration among
distant cortical areas [38]. In particular, white matter
alterations are the feature of subcortical ischemic vas-
cular disease (SIVD) that helps establish a diagnosis.
However, there is only limited correlation in SIVD be-
tween cognition and the extent of white matter alterations
observed by standard MRI sequences such as FLAIR [39].
In contrast, diffusion-weighted imaging can characterize
microstructural alterations in the normal-appearing white
matter, which is also affected in VCI due to local path-
ology as well as Wallerian degeneration from distant le-
sions. Diffusion MRI indices of normal-appearing white
matter exhibit a higher correlation with cognition than
conventional MRI markers [40]. Another advantage of the
use of diffusion MRI in SIVD is that it provides quantita-
tive markers of tissue integrity [41].
The contrast provided by diffusion MRI is based on
the thermal motion of water molecules, which is hin-
dered by cellular membranes and myelin sheaths [42]. In
most cases, diffusion is anisotropic in organized white
matter structures, where it exhibits directional prepon-
derance. On the other hand, diffusion is isotropic in
areas where there is less microstructural organization of
white matter fibers such as grey matter or cerebrospinal
fluid [43]. Several indices of white matter integrity can
be calculated. Mean diffusivity quantifies the extent of
total diffusivity in a given voxel, whilst axial and radial
diffusivity quantify the amount of diffusion along and
perpendicular to its main direction, respectively. Another
commonly applied metric is that of fractional anisotropy,
which is a relative measure that quantifies the amount of
directional preponderance of diffusion in a given voxel.
Diffusion MRI indices are changing both with healthy age-
ing and disease. Cellular damage leads, in general, to less
restricted diffusion and, in turn, to an increase in absolute
diffusivity and decreased anisotropy. Fractional anisotropy
is highly sensitive to microstructural changes, but is not
very specific to the type of change. Mean, axial, and radial
diffusivity provide complementary information on the
nature of microstructural alterations. However, there is no
simple relationship between individual metrics and white
matter integrity, and it is advantageous that several
metrics are used to provide a fuller characterization of
microstructural alterations [44, 45]. These can be assessed
at various spatial scales.
Histogram distributions of diffusion metrics provide
useful markers of the disease process that are sensitive
to change [46] and correlate well with clinical progression
[47, 48]. In CADASIL, a mean diffusivity value has been
identified as the main predictor of clinical progression
among other demographic, clinical, and conventional MRI
markers for various clinical endpoints, including disability,
cognition, and newly occurring strokes [48]. Histogram
measures are highly reproducible and thus provide robust
summary statistics in SIVD [49]. One of their limitations
is that they do not provide information solely on intrinsic
microstructural changes, but are also influenced by volu-
metric alterations, which can introduce bias in populations
prone to atrophy, but can be corrected using post-
processing techniques [50]. In addition to global summary
measures, diffusion MRI can be used to estimate the
spatial profile of white matter alterations. Voxel-wise ana-
lyses, as well as tractography studies, have demonstrated
critical areas within the damaged white matter that cor-
relate most strongly with aspects of cognition such as
executive function or verbal memory [51–53]. Estimating
white matter alterations in individual regions or single
tracts can explain the profile of cognitive impairment in a
given patient with VCI as well as helping to understand
the relative importance of a small number of strategically-
located lesions versus the cumulative effect of multiple
lesions; both could prove fruitful longitudinal studies
on disease progression as well as intervention studies.
Whole-brain tractograms can be used to reconstruct
white matter structural networks. Their topology mea-
sures are quantified using graph theory-based metrics
such as measures of network integration. Networks of
patients with SIVD and cerebral amyloid angiopathy ex-
hibit a less efficient topology associated with cognitive
decline [54, 55]. Network metrics have been shown to
partly or fully explain the association between cognition
and other MRI measures commonly used in SIVD, in-
cluding mean fractional anisotropy and mean diffusivity
[54]. Thus, network metrics provide useful markers of
the disease process as well as suggesting the importance
of network disruption as a potential common mechanism
of how different types of vascular damage can lead to
cognitive decline.
Diffusion MRI allows assessment of subtle alterations
in SIVD that are not captured by other imaging tech-
niques and provides several markers of micro- and
macrostructural organization that are sensitive to change
and related to important clinical endpoints. Linking
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different levels of spatial analysis remains an important
challenge in understanding the pathophysiology of SIVD
and cognitive decline. Importantly, it also has the poten-
tial to predict cognitive trajectories in individual patients
as well as to help establish a diagnosis; however, further
studies are required in these areas.
Proton MR spectroscopy and dynamic contrast-enhanced
MRI
Detection of ischemic changes in white matter as opposed
to those due to aging is possible with proton magnetic res-
onance spectroscopy (1H-MRS), diffusion tensor imaging,
and dynamic contrast-enhanced MRI (DCEMRI). 1H-
MRS shows injury to the axons by measuring the levels of
N-acetylaspartate and creatine [56, 57]. Diffusion tensor
imaging provides another indicator of structural damage
to white matter [58]. Finally, DCEMRI is a functional
measure of the leakiness of blood vessels, which indicates
the presence of neuroinflammation [59, 60]. The combin-
ation of multiple modalities provides a clear picture of
the extent of damage and the possible etiology of the
injury in white matter. Using these modalities, white
matter changes due to ageing can be separated from
structural and functional changes due to pathology.
An important aspect of the pathological changes seen
in the small vessel type of VCI is the measurement of
blood–brain barrier (BBB) permeability. Quantitative
regional measurements of BBB can be made with
DCEMRI, which requires the injection of MRI contrast
agents [59]. They also have high computational needs
and remain unstandardized so that values from different
sites are difficult to compare.
There is general agreement that the small vessel form
of VCI, which generally causes progressive damage to
white matter, is the optimal form for treatment trials.
The major challenges facing the next stage of VCI im-
aging research are (1) the identification of imaging pat-
terns characteristic of Binswanger’s disease, and (2) the
selection of the imaging modalities that undergo changes
over time and which could be used as surrogate markers
for treatment trials [61].
Molecular imaging in the differential diagnosis of vascular
dementia
Positron emission tomography (PET) can support the
clinical diagnosis by visualizing cerebral functions in typic-
ally affected brain regions. PET of 18F-2-fluoro-2-deoxy-
D-glucose (FDG) for measurement of regional cerebral
glucose metabolism (rCMRglc) has shown a typical meta-
bolic pattern in patients with probable AD: hypometabo-
lism in temporoparietal and frontal association areas, but
relative recessing of primary cortical areas, basal ganglia,
and cerebellum (Fig. 1). In VCI, a different pattern is seen
(review in [62]), where FDG-PET detects regions of focal
cortical and subcortical hypometabolism, a metabolic
pattern different from that typical for AD with marked
hypometabolism affecting the association areas [63]. A
significant reduction of rCMRglc was observed in wide-
spread cerebral regions (middle frontal cortex, temporo-
parietal cortex, basal ganglia, cerebellum, and brainstem)
[64]. Hypometabolism was more marked in subcortical
areas and primary sensorimotor cortex and the association
areas were less affected than in AD. A metabolic ratio
(rCMRglc of association areas divided by rCMRglc of pri-
mary areas, basal ganglia, cerebellum, and brainstem) was
significantly lower in AD than in VCI. A single region that
could discriminate between VCI and AD could not be
identified, but small infarcts, in combination with WMHs,
may contribute to cognitive decline. Rather than the total
volume of infarction, data from PET studies indicate that
the volume of functional tissue loss is more important
than the extent of morphological lesions, since this in-
cludes incompletely infarcted tissue and morphologically
intact but deafferented cortex.
The accuracy of rCMRglc changes for the clinical diag-
nosis of AD has only been investigated in few reports.
An analysis of receiver operating characteristics recorded
93 % sensitivity and 83 % specificity for differentiation of
patients with probable AD from those without AD or
other dementing illnesses [65]. A significantly abnormal
metabolic ratio in subjects with mild cognitive impair-
ment (MCI) indicated a high risk to develop dementia
Fig. 1 Typical metabolic patterns for different types of dementia
compared to normal controls and vascular dementia (VD).
Alzheimer’s disease (AD), frontotemporal dementia (FTD), and
Lewy-Body dementia (LBD) show distinct cortical patterns of
decreased metabolism, while multisystem atrophy type P (MSD-P)
shows a decreased metabolism in the putamen on both sides. In
contrast, a typical feature of VD is the simultaneous occurrence
of patchy, often asymmetrical cortical and subcortical areas of
decreased glucose metabolism
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within the next 2 years. SIVD could be distinguished
from clinically probable AD by a more diffuse pattern of
hypometabolism involving also the primary cortices,
basal ganglia, thalamus, and cerebellum.
Characteristic patterns of regional hypometabolism are
also seen in other degenerative dementias (review in [66])
(Fig. 1), such as frontotemporal dementia, clinically con-
spicuous by changes in personality and behavior, semantic
deficits, and progressive aphasia associated with distinct
often asymmetric frontal or frontotemporal metabolic
changes that are typically centered in the frontolateral
cortex and the anterior pole of the temporal lobe. DLB,
namely fluctuating consciousness, Parkinsonian symp-
toms, and impairment of visual perception including
hallucinations, is characterized by a reduction of glucose
metabolism in the primary visual cortex in addition to that
in posterior association areas. Other degenerative dis-
orders show typical hypometabolism in the specifically
affected brain structures: the putamen and cortex in
corticobasal degeneration, the caudate nucleus in
Huntington’s disease, the frontal cortex and midbrain in
progressive supranuclear palsy, and pons and cerebellum
in olivopontocerebellar atrophy. Depressive disorders may
mimic cognitive impairment; in these cases, glucose me-
tabolism does not show regional abnormalities typical for
the degenerative disorders [67].
Imaging synaptic transmission and accumulation of
pathologic proteins
Additional PET tracers can further support the diagnosis
of a type of dementia and also yield information on the
underlying pathophysiology. Tracers permit the study of
selectively affected transmitter/receptor systems, e.g., the
cholinergic system in AD, where a significant reduction
of cholinergic activity in the cortex of AD patients and
those with MCI and early conversion to AD is observed
[68], or the dopaminergic system in DLB [69] and the
detection of pathogenetic depositions, e.g., amyloid and
tau in AD [70] or inflammatory reactions with microglia
activations as in VCI. In particular, the imaging of ac-
cumulation of pathologic proteins is a recent strategy
to differentiate degenerative dementias. Amyloid is a
pathogenetic product in the development of AD and its
accumulation is a key finding in this disease (Fig. 2)
and can be imaged by 11C-labeled Pittsburgh Compound
B (PiB) [71] or by several newer 18F-labeled tracers [72].
Whereas only small amounts of amyloid can be detected
in white matter in normal aging [73], accumulation is vis-
ible in the frontal and temporoparietal cortex in AD and
MCI. However, in 20–30 % of aged persons without
relevant cognitive impairment, an increased accumula-
tion of amyloid can also be detected [74], and the grade
of amyloid deposition as detected by PET is not related
to the severity of cognitive impairment [75]. Therefore,
amyloid might be deposited in the brain long before
cognitive impairment is recognized.
A more specific pathologic protein produced in AD is
tau, and its deposition in the mesial temporal lobe is an
early marker of AD or MCI [76], with the amount of tau
detected in the cortex by selective PET-tracers being re-
lated to the severity of cognitive impairment [77]. These
PET-tracers also detect the primary pathological substrate
Fig. 2 An 82-year-old man with cognitive decline 6 months after right parietal ischemic stroke. 11-C-PIB-PET shows amyloid deposits in brain
regions typical for Alzheimer’s disease, thus differentiating Alzheimer’s dementia from post-stroke dementia as a possible differential diagnosis
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in other degenerative dementias (e.g., tau in frontotemporal
dementia) [78] and permit the differentiation between AD
and VCI and other degenerative dementias. As these
studies provide insight on the early changes of these
diseases, selective PET-studies might be useful to detect
preclinical stages in which therapeutic efforts might be
promising.
PET and imaging of neuroinflammation
Using amyloid imaging tracers such as 11C-PiB, it has
been shown that patients with radiologically defined
SIVD and amyloid deposits were, on average, older, had
worse cognitive performance, fewer lacunar infarcts, and
more hippocampal atrophy than amyloid-negative patients.
Amyloid deposits were observed in approximately 30 % of
patients with radiologically-defined VCI. These findings
may indicate a synergistic effect of amyloid depositions and
vascular lesions since both are known risk factors for devel-
oping dementia [79, 80]. In analogy to these clinical studies,
animal models suggest that it may be stroke-induced in-
flammation (rather than the ischemic event itself) which
acts synergistically with amyloid depositions and accelerates
cognitive decline [81]. Direct proof for this relationship,
however, remains to be established in human stroke.
Several PET tracers (such as 11C-[R]-PK11195 and
others) have been developed to measure the activity of
microglia (the most important cellular marker of neuro-
inflammation) in the ischemic brain in vivo and can be
used to address these questions [82]. While a direct rela-
tionship between cortical microglia activity and cognitive
performance in dementia remains to be demonstrated
[6, 83], it is known, from post mortem [84] and in vivo
imaging studies [85], that ischemia-induced neuroin-
flammation can trigger ongoing neurodegenerative pro-
cesses of fiber tracts. This inflammation-associated tract
degeneration does not only directly affect neurons that
were subject to ischemia but can spread trans-synaptically
[86] and thus compromise larger scale networks. In a
pilot study, two PET-scans were performed 5–7 months
following an ischemic stroke to assess amyloid deposition
(11C-PiB) and microglia activation (11C-[R]-PK11195).
Cognitive performance 5–7 months after the stroke was
negatively correlated with gray matter amyloid deposition
and this relationship remained significant even when ini-
tial cognitive performance and age were entered as covari-
ates into the analysis. Similarly, microglia activation in the
stroke-affected hemisphere white matter was highly corre-
lated with cognitive performance [87]. The results of this
study in human stroke may suggest that cortical amyloid
deposition and post-stroke white matter inflammation
contribute to post-stroke cognitive impairment and may
constitute separate pathomechanisms to explain cognitive
decline. If confirmed in larger trials, this finding might
offer possibilities for clinical intervention to prevent post-
stroke cognitive decline by modulation of inflammation or
amyloid deposition.
Conclusions
Neuroimaging will continue to play a leading role in the
diagnosis of patients with dementia. While MRI is the
most widely used modality and is available in most cen-
ters, PET offers the ability to distinguish between the
vascular and neurodegenerative causes of dementia. Fur-
ther, 1H-MRS, diffusion tensor imaging, and DCEMRI
augment clinical MRI studies by showing ischemic dam-
age to white matter and disruption of the BBB, a major
factor in neuroinflammation. It is important to separate
patients with mainly AD from those with mainly VCI;
however, in reality, the majority of patients appear to
have combinations of both. Planning clinical trials of pa-
tients with VCI is a critical need, and the ability to more
clearly delineate between AD, VCI, and mixed pathology
will be crucial to reduce the number of patients needed
for a trial. A longitudinal study comparing the development
of clinical symptoms with changes in imaging, including
various MRI parameters and eventually quantitative data
from PET followed by validation through neuropathological
confirmation, would be the ideal basis for long-term treat-
ment studies.
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